Ruidi Pharmaceutical

Ruidi Pharmaceutical is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics for metabolic diseases and oncology. The company's primary focus is on the incretin pathway, developing oral small molecule agonists that target the GLP-1, GIP, and Glucagon receptors. Its lead candidate, RD-01, is a potent oral small molecule GLP-1 receptor agonist currently in Phase 2 clinical trials for type 2 diabetes and obesity. Ruidi aims to provide more convenient and effective oral alternatives to traditional injectable peptide therapies, addressing significant unmet needs in the global metabolic health market. The company leverages an advanced medicinal chemistry platform to optimize the pharmacological profiles of its multi-target incretin candidates.